title: The original sin committed in years two thousand.
abstract: Contemporary treatment of ST segment elevation myocardial infarction requires the use of potent antithrombotic drugs. Glycoprotein IIb/IIIa inhibitors, especially abciximab, have been used diffusely in the last 10 years to help obtain procedural success and conversely to improve clinical outcome. However, the increased bleeding rate associated with this class of drugs is still a matter of concern. This editorial comments on the results of some recently published papers on these "old" drugs, with the auspice of looking at newer, safer drugs.
authors.forename: Bernardo
authors.initials: B
authors.lastname: Cortese
mesh_terms: D000077284:Abciximab; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use; D000925:Anticoagulants / Q000009:adverse effects / Q000627:therapeutic use; D000077542:Eptifibatide; D005343:Fibrinolytic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000009:adverse effects / Q000627:therapeutic use; D009203:Myocardial Infarction / Q000188:drug therapy*; D010455:Peptides / Q000009:adverse effects / Q000627:therapeutic use; D010975:Platelet Aggregation Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000037:antagonists & inhibitors*
chemical_list: D000911:Antibodies, Monoclonal; D000925:Anticoagulants; D005343:Fibrinolytic Agents; D007140:Immunoglobulin Fab Fragments; D010455:Peptides; D010975:Platelet Aggregation Inhibitors; D019039:Platelet Glycoprotein GPIIb-IIIa Complex; D000077542:Eptifibatide; D000077284:Abciximab